Why Did Ru Never Make It To Market?
- Thread starter CodyJ
- Start date
- Reaction score
- 134
No one actually knows the real reason why the trials were discontinued.
- Reaction score
- 134
It’s a weak AA. You need large doses or prolonged use to see any significant results unless you are a lucky ‘hyper responder’ which has been reported.
A large dose of any AA in a topical solution could potentially be dangerous to anyone around who isn’t trying to block androgen receptors or play with their horomones. Maybe this is why it never ‘made it,’ and maybe not.
It does work. There are no reports of cancer.
A large dose of any AA in a topical solution could potentially be dangerous to anyone around who isn’t trying to block androgen receptors or play with their horomones. Maybe this is why it never ‘made it,’ and maybe not.
It does work. There are no reports of cancer.
- Reaction score
- 563
The problem is there are no long term studies.
- Reaction score
- 134
Plenty of long term users. No science to suggest it may be carcinogenic. Anti androgens have apoptic effects, they are used to treat cancer.
- Reaction score
- 563
Just say you don't know.
- Reaction score
- 134
lol hmmm to assume something may cause cancer for no reason ...
Last edited:
- Reaction score
- 563
Never said it did, just said it makes me think it did. You are the one saying it doesn't and may even be chemopreventive...
- Reaction score
- 134
Nice
- Reaction score
- 6,987
i do find it bizarre why there are no official statements as to why testing was stopped for this
i assume its because of the possible dangers to pregnant women and it being a pain in the *** for customers to use, and not because of any horror findings in their studies, but id still like some official word on it
surely if there were any they would have reported it
i assume its because of the possible dangers to pregnant women and it being a pain in the *** for customers to use, and not because of any horror findings in their studies, but id still like some official word on it
surely if there were any they would have reported it
- Reaction score
- 134
I feel the same.
- Reaction score
- 221
There's have been countless threads about this over the years. The main issues were money and patent issues. No company thought it was worth it and then the patent expired. If I had to guess, it's because of the stability issues. You can't mass produce this like minoxidil. The company would have to sell powder that people would mix themselves. It's hard enough to sell a topical. I don't think there would been a large market out there for this.
My theory sort of confirmed here: https://www.hairlosscure2020.com/the-strange-predicament-of-ru58841/
My theory sort of confirmed here: https://www.hairlosscure2020.com/the-strange-predicament-of-ru58841/
- Reaction score
- 129
It's quite funny, all types of SSRI are available so you find which one you respond best to, yet the hairloss market only wants a swiss army knife which inevitably leaves some in the dust. I imagine hairloss has a higher prevalence, and we have to deal with the strange case of women, I'm surprised there isn't more demand.
- Reaction score
- 134
Irrelevant but wait, are you really 15 ?
- Reaction score
- 129
...No?...
- Reaction score
- 129
Yeah says I had to talk to an admin so I just hid it for now.
- Reaction score
- 134
Sorry bout that lol it says you are on your profile thing for some reason. I thought who talks like that at 15 ?
What did you mean by a Swiss Army knife ?
- Reaction score
- 129
Lol that's cool, I wasn't are I accidentally dialed in the wrong year.
I mean just an AA that works pretty well in most cases, finasteride etc. Years ago we just had Prozac, now we've got all types of stuff.
- Reaction score
- 11,938
Ignore the other misinformation on this thread.
It's actually well known why RU did not make it to market, and it's been previously posted on this site. The company simply estimated that RU would not be that profitable, and thus it did not other with phase III clinical trials, marketing, etc.
It's not that hard to see why. This is a small market, and RU was measured to be comparably effective to existing treatments, rather than more effective. If it had been better, they would have released it.